We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
(Approval lapsed) BEYFORTUS nirsevimab 50mg/0.5mL injection solution in pre-filled syringe (Chile)
Section 19A approved medicine
(Approval lapsed) BEYFORTUS nirsevimab 50mg/0.5mL injection solution in pre-filled syringe (Chile)
Section 19A approval holder
Sanofi-aventis Australia Pty Ltd ABN 31 008 558 807
Phone
1800 818 806
Approved until
Status
Expired
Medicines in short supply/unavailable
BEYFORTUS nirsevimab 50mg in 0.5mL solution for injection prefilled syringe - ARTG 397898
Indication(s)
BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:
- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
BEYFORTUS should be used in accordance with official recommendations.
Images
